Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

Teva Pharmaceutical Industries TEVA reported third-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks ...

Shares of Teva Pharmaceutical (NYSE:TEVA) gained in the premarket trading on Wednesday after the generic drugmaker reported better-than-expected Q3 2024 financials and raised its full-year outlook ...

was about creating a sustainable generics powerhouse,” Francis said in an interview with Fierce Pharma on Wednesday. “In no way were we in a sense stepping away from generics.” Teva said the ...

The United States Department of Justice (DOJ) recently announced that Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. will pay $450 million to resolve allegations of violating the ...

Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical ... Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA0.70%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...

Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by rival generic drugmakers, the company’s second major financial ...

Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust watchdog for thwarting fair competition by unfairly disparaging a rival ...

BRUSSELS, Oct 31 (Reuters) - Teva (TEVA.TA), opens new tab ... "We send a clear message to dominant pharmaceutical companies that we will not tolerate the use of disparagement campaigns to ...

Oct. 31 (UPI) --The European Commission fined Teva Pharmaceuticals $503 million for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.